Hangzhou-based Valgen Holding Corporation has received market approval from the National Medical Products Administration (NMPA) for its innovative DragonFly transcatheter mitral valve clamp system, marking it as the first of its kind in China.
The DragonFly system is designed for use in transcatheter mitral valve edge-to-edge repair (TEER) procedures and is currently undergoing clinical trials across 27 centers in China, with over 300 cases reported to date. Preliminary data indicates strong controllability, long-term safety, and efficacy, positioning DragonFly as a significant advancement in cardiac intervention technology.- Flcube.com
